Swiss pharmaceutical giant Novartis (NYSE: NVS) has published results from a Phase III study of its CDK4/6 inhibitor Kisqali (ribociclib) in combination with endocrine therapy (ET) as an adjuvant treatment for HR+/HER2- early breast cancer (EBC). The data, recorded for up to three years, indicated that Kisqali reduced the risk of cancer recurrence by 25.2% compared to ET alone. Importantly, patients maintained their physical functioning and global health scores as per patient-reported outcomes, suggesting that the clinical benefits of Kisqali are not accompanied by an increased burden of care.
Kisqali’s Global Approvals and Ongoing Trial Analysis
Kisqali has received global approvals as a treatment for HR+/HER2- advanced or metastatic breast cancer. The positive results from the Phase III study further solidify its potential role in the treatment of early breast cancer. Additional results from the trial are anticipated upon completion of the analysis, which could provide further insights into the drug’s efficacy and safety profile in this patient population.-Fineline Info & Tech
